Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction

• DOI: 10.1097/hjh.0b013e3282efeecb
• Publication Date: 2009-03-04T00:06:23Z
• Authors: María J Pires; Ana B Rodríguez-Peña; Miguel Arévalo; Begoña Cenador; Stefano Evangelista; Alejandro Esteller; Ángel Sánchez-Rod...; Aura Colaço; José M López-Novoa
• Keywords: Nebivolol; Endothelial Dysfunction; Renal mass

D/L-Nebivolol is a lypophilic beta1-adrenergic antagonist which devoid of intrinsic sympathomimetic activity and can increase nitric oxide (NO) bioavailability with its subsequent vasodilating properties. The purpose the present work was to assess effect long-term nebivolol administration on both renal damage endothelial dysfunction induced by mass reduction (RMR) in rats. Atenolol, does not NO bioavailability, included study as comparative beta-adrenoceptor antagonist. Rats were subjected right nephrectomy surgical removal two-thirds left kidney order retain approximately one-sixth total mass. One week after ablation, rats distributed randomly according following experimental groups: control group containing RMR without treatment; treated daily for 6 months (drinking water, 8 mg/kg per day); atenolol 80 day). A sham-operated animals also included. Administration either or similarly reduced arterial pressure comparison untreated animals; however, receiving presented lower levels collagen type I expression well glomerular interstitial fibrosis than those atenolol. Urinary excretion oxidative stress markers Furthermore, prevented RMR-induced more efficiently Nebivolol protects against fibrosis, better equivalent doses, terms reduction, hypertensive model RMR.